Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RYSTIGGO 140 MG/ML SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RYSTIGGO 140 MG/ML SOLUCION INYECTABLE

Approved

STANDARD

RYSTIGGO 140 MG/ML SOLUCION INYECTABLE

Ucb Pharma🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 5, 2024
Approval ID: 830471f5c0edc67c
Company: Ucb Pharma
Type: Standard

Approval Details

Approval Id: 830471f5c0edc67c
Drug Cima Aemps Name: RYSTIGGO 140 MG/ML SOLUCION INYECTABLE
Register Number: 1231780001
Holder Company Name: Ucb Pharma
Marketing Company Name: Ucb Pharma S.A.
Holder Company Detail Path: /organization/ucb-pharma-sa
Marketing Company Detail Path: /organization/ucb-pharma-sa-switzerland
Authorization Date: 2024-02-05
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 140 mg/ml
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Ucb Pharma
Company Detail Path: /organization/ucb-pharma-sa

Company Information

Pharmaceutical Company Name: UCB S.A.
Name En: UCB S.A.
Country Name: Belgium
City Name: Brussels
Address: Brussels, Belgium
Website: https://www.ucb.com

Active Ingredients

ROZANOLIXIZUMAB

280 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 5, 2024

Approval ID

830471f5c0edc67c

Type

Standard

Back to CIMA-AEMPS Approvals